Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Adrenal Gland Pheochromocytoma
- Recurrent Ectomesenchymoma
- Refractory Ewing Sarcoma
- Recurrent Ependymoma
- Recurrent Soft Tissue Sarcoma
- Refractory Rhabdoid Tumor of the Kidney
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Rhabdomyosarcoma
- Recurrent Ewing Sarcoma
- Recurrent Rhabdoid Tumor of the Kidney
- Refractory Hepatoblastoma
- Refractory Rhabdomyosarcoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Adrenal Gland Pheochromocytoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Refractory Non Hodgkin Lymphoma
- Refractory Rhabdoid Tumor
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Osteosarcoma
- Refractory Ependymoma
- Refractory Langerhans Cell Histiocytosis
- Recurrent Kidney Wilms Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Glioma
- Recurrent Osteosarcoma
- Refractory Neuroblastoma
- Recurrent Medulloblastoma
- Recurrent WHO Grade II Glioma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory WHO Grade II Glioma
- Recurrent Melanoma
- Recurrent Neuroblastoma
- Refractory Thyroid Gland Carcinoma
- Refractory Melanoma
- Refractory Soft Tissue Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 1221 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tipifarnib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alter...
PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tipifarnib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in HRAS. SECONDARY OBJECTIVES: I. To estimate the progression free survival in pediatric patients treated with tipifarnib with advanced solid tumors (including CNS tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in HRAS. II. To obtain information about the tolerability of tipifarnib in children and adolescents with relapsed or refractory cancer. EXPLORATORY OBJECTIVES: I. To evaluate other biomarkers as predictors of response to tipifarnib and specifically, whether tumors that harbor different missense mutations or variant allele frequency will demonstrate differential response to tipifarnib treatment. II. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA). OUTLINE: Patients receive tipifarnib orally (PO) or via nasogastric or gastric tube twice daily (BID) on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, then periodically thereafter.
Tracking Information
- NCT #
- NCT04284774
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Christine A Pratilas Children's Oncology Group
Get Well Soon